Avanir's Neurodex NDA Delayed by FDA Data Request

Drug Industry Daily
KEYWORDS Drug Approvals / NDA
A A

Avanir Pharmaceuticals expects its new drug application (NDA) for Neurodex to be delayed, following an FDA request for additional data on the drug.

To View This Article:

Login

Subscribe To Drug Industry Daily